ArticleLeukemia2021

Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma.

Saad Z Usmani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.